Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition. Chiablaem K, Lirdprapamongkol K*, Keeratichamroen S, Surarit R, Svasti J. Anticancer Res. 2014 Apr;34(4):1857-64.

01 Apr 2014
0
0

Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition.

Chiablaem K, Lirdprapamongkol K*, Keeratichamroen S, Surarit R, Svasti J.

Anticancer Res. 2014 Apr;34(4):1857-64.

Tags

Share this

Related Posts

Jongcharoenkamol, J.; Chuathong, P; Amako, Y.; Kono, M.; Poonswat, K.; Ruchirawat, S; Ploypradith, P. Selective Divergent Synthesis of Indanols, Indanones, and Indenes via Acid-Mediated Cyclization of (Z)- and (E)-(2-Stibenyl)methanols and its Application for the Synthesis of Paucifloral F Derivatives. J. Org. Chem. 2018, 83, 13184–13210.
28 Dec 2018
0

Jongcharoenkamol, J.; Chuathong, P; Amako, Y.; Kono, M.; Poonswat, K.; Ruchirawat, S; Ploypradith, P. Selective Divergent Synthesis of Indanols, Indanones, and Indenes via Acid-Mediated Cyclization of (Z)- and (E)-(2-Stibenyl)methanols and its Application for the Synthesis of Paucifloral F Derivatives. J. Org. Chem. 2018, 83, 13184–13210.

Jongcharoenkamol, J.; Chuathong, P; Amako, Y.; Kono, M.; Poonswat, K.; Ruchirawat, S; Ploypradith, P. Selective Divergent Synthesis of Indanols, Indanones, and Indenes via Acid-Mediated Cyclization of (Z)- and (E)-(2-Stibenyl)methanols and its Application for the Synthesis of Paucifloral F Derivatives. J. Org. Chem. 2018, 83, 13184–13210.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More